|
1
|
Janot F, de Raucourt D, Benhamou E, Ferron
C, Dolivet G, Bensadoun RJ, Hamoir M, Géry B, Julieron M, Castaing
M, et al: Randomized trial of postoperative reirradiation combined
with chemotherapy after salvage surgery compared with salvage
surgery alone in head and neck carcinoma. J Clin Oncol.
26:5518–5523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tao Y, Faivre L, Laprie A, Boisselier P,
Ferron C, Jung GM, Racadot S, Gery B, Even C, Breuskin I, et al:
Randomized trial comparing two methods of re-irradiation after
salvage surgery in head and neck squamous cell carcinoma: Once
daily split-course radiotherapy with concomitant chemotherapy or
twice daily radiotherapy with cetuximab. Radiother Oncol.
128:467–471. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP
and Morris LG: Decision making in the management of recurrent head
and neck cancer. Head Neck. 36:144–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oliva M, Spreafico A, Taberna M, Alemany
L, Coburn B, Mesia R and Siu LL: Immune biomarkers of response to
immune-checkpoint inhibitors in head and neck squamous cell
carcinoma. Ann Oncol. 30:57–67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Phulpin B, Dolivet G, Marie PY, Poussier
S, Gallet P, Leroux A, Graff P, Groubach F, Bravetti P, Merlin JL
and Tran N: Re-assessment of chronic radio-induced tissue damage in
a rat hindlimb model. Exp Ther Med. 1:553–560. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallet P, Phulpin B, Merlin JL, Leroux A,
Bravetti P, Mecellem H, Tran N and Dolivet G: Long-term alterations
of cytokines and growth factors expression in irradiated tissues
and relation with histological severity scoring. PLoS One.
6:e293992011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zeng J, See AP, Phallen J, Jackson CM,
Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E,
et al: Anti-PD-1 blockade and stereotactic radiation produce
long-term survival in mice with intracranial gliomas. Int J Radiat
Oncol Biol Phys. 86:343–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Formenti SC, Rudqvist NP, Golden E, Cooper
B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari
de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces
responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saâda-Bouzid E, Defaucheux C, Karabajakian
A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J,
Loirat D, et al: Hyperprogression during anti-PD-1/PD-L1 therapy in
patients with recurrent and/or metastatic head and neck squamous
cell carcinoma. Ann Oncol. 28:1605–1611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Champiat S, Ferrara R, Massard C, Besse B,
Marabelle A, Soria JC and Ferté C: Hyperprogressive disease:
Recognizing a novel pattern to improve patient management. Nat Rev
Clin Oncol. 15:748–762. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith J, Robida MD, Acosta K, Vennapusa B,
Mistry A, Martin G, Yates A and Hnatyszyn HJ: Quantitative and
qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Diagn Pathol. 11:442016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fakhry C, Lacchetti C, Rooper LM, Jordan
RC, Rischin D, Sturgis EM, Bell D, Lingen MW, Harichand-Herdt S,
Thibo J, et al: Human papillomavirus testing in head and neck
carcinomas: ASCO clinical practice guideline endorsement of the
college of American pathologists guideline. J Clin Oncol.
36:3152–3161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ono T, Azuma K, Kawahara A, Sasada T,
Hattori S, Sato F, Shin B, Chitose SI, Akiba J and Hirohito U:
Association between PD-L1 expression combined with
tumor-infiltrating lymphocytes and the prognosis of patients with
advanced hypopharyngeal squamous cell carcinoma. Oncotarget.
8:92699–92714. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Solomon B, Young RJ, Bressel M, Urban D,
Hendry S, Thai A, Angel C, Haddad A, Kowanetz M, Fua T, et al:
Prognostic significance of PD-L1+ and CD8+
Immune cells in HPV+ oropharyngeal squamous cell
carcinoma. Cancer Immunol Res. 6:295–304. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on T-cell infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rosenbaum PR: Optimal matching for
observational studies. J Am Stat Assoc. 84:1024–1032. 1989.
View Article : Google Scholar
|
|
23
|
Yuan J, Hegde PS, Clynes R, Foukas PG,
Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB,
et al: Novel technologies and emerging biomarkers for personalized
cancer immunotherapy. J Immunother Cancer. 4:32016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang WF, Wong MCM, Thomson PJ, Li KY and
Su YX: The prognostic role of PD-L1 expression for survival in head
and neck squamous cell carcinoma: A systematic review and
meta-analysis. Oral Oncol. 86:81–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gooden MJM, de Bock GH, Leffers N, Daemen
T and Nijman HW: The prognostic influence of tumour-infiltrating
lymphocytes in cancer: A systematic review with meta-analysis. Br J
Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thomas NE, Busam KJ, From L, Kricker A,
Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R,
Rosso S, et al: Tumor-infiltrating lymphocyte grade in primary
melanomas is independently associated with melanoma-specific
survival in the population-based genes, environment and melanoma
study. J Clin Oncol. 31:4252–4259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Balermpas P, Rödel F, Krause M, Linge A,
Lohaus F, Baumann M, Tinhofer I, Budach V, Sak A, Stuschke M, et
al: The PD-1/PD-L1 axis and human papilloma virus in patients with
head and neck cancer after adjuvant chemoradiotherapy: A
multicentre study of the German cancer consortium radiation
oncology group (DKTK-ROG). Int J Cancer. 141:594–603. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Champiat S, Dercle L, Ammari S, Massard C,
Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A,
Soria JC and Ferté C: Hyperprogressive disease is a new pattern of
progression in cancer patients treated by anti-PD-1/PD-L1. Clin
Cancer Res. 23:1920–1928. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun XS, Sire C, Tao Y, Martin L, Alfonsi
M, Prevost JB, Rives M, Lafond C, Tourani JM, Biau, et al: A phase
II randomized trial of pembrolizumab versus cetuximab, concomitant
with radiotherapy (RT) in locally advanced (LA) squamous cell
carcinoma of the head and neck (SCCHN): First results of the GORTEC
2015-01 ‘PembroRad’ trial. J Clin Oncol. 36 (15 Suppl):S60182018.
View Article : Google Scholar
|
|
32
|
Zandberg DP, Algazi AP, Jimeno A, Good JS,
Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, et
al: Durvalumab for recurrent or metastatic head and neck squamous
cell carcinoma: Results from a single-arm, phase II study in
patients with ≥25% tumour cell PD-L1 expression who have progressed
on platinum-based chemotherapy. Eur J Cancer. 107:142–152. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu Y, Wang H, Yan A, Wang H, Li X, Liu J
and Li W: Pretreatment neutrophil to lymphocyte ratio in
determining the prognosis of head and neck cancer: A meta-analysis.
BMC Cancer. 18:3832018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lei Y, Xie Y, Tan YS, Prince ME, Moyer JS,
Nör J and Wolf GT: Telltale tumor infiltrating lymphocytes (TIL) in
oral, head & neck cancer. Oral Oncol. 61:159–165. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Psyrri A, Gavrielatou N, Spathis A,
Anastasiou M, Fortis E, Gkotzamanidou M, Kladi-Skandali A, Kousidou
E, Economopoulou P, Kotsantis I, et al: Predictive biomarkers for
response to nivolumab in head and neck squamous cell carcinoma
(HNSCC) (NCT#03652142). J Clin Oncol. 37 (Suppl 15):S60602019.
View Article : Google Scholar
|
|
36
|
Mehanna H, West CM, Nutting C and Paleri
V: Head and neck cancer-Part 2: Treatment and prognostic factors.
BMJ. 341:c46902010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cadoni G, Giraldi L, Petrelli L,
Pandolfini M, Giuliani M, Paludetti G, Pastorino R, Leoncini E,
Arzani D, Almadori G and Boccia S: Prognostic factors in head and
neck cancer: A 10-year retrospective analysis in a
single-institution in Italy. Acta Otorhinolaryngol Ital.
37:458–466. 2017.PubMed/NCBI
|
|
38
|
Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW,
Choi EC, Kim EK, Pyo KH, Jung I, Seo D, et al: PD-L1 expression on
immune cells, but not on tumor cells, is a favorable prognostic
factor for head and neck cancer patients. Sci Rep. 6:369562016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE,
Even C, et al: Nivolumab vs. investigator's choice in recurrent or
metastatic squamous cell carcinoma of the head and neck: 2-year
long-term survival update of CheckMate 141 with analyses by tumor
PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
|
